Endocrine disrupting chemicals (EDC) are compounds that alter the normal functioning of the endocrine system of both wildlife and humans. A huge number of chemicals have been identified as endocrine disruptors, among them several pesticides. Pesticides are used to kill unwanted organisms in crops, public areas, homes and gardens, and parasites in medicine. Human are exposed to pesticides due to their occupations or through dietary and environmental exposure (water, soil, air). For several years, there have been enquiries about the impact of environmental factors on the occurrence of human pathologies. This paper reviews the current knowledge of the potential impacts of endocrine disruptor pesticides on human health.

a b s t r a c tThe aim of the present paper is to provide a quantitative prediction of the elastic-damage behaviour of randomly oriented fiber polymer composites. A constitutive model based on micromechanical considerations is presented. The nucleation and growth of voids induced by progressive fiber debonding is combined with the constitutive relationship. Failure resulting of excessive damage accumulation is captured by a critical void volume criterion and a vanishing element technique. Experimentally, damage accumulation in random glass fiber-polyester composites was monitored by a videoextensometry technique able to control the local strain rate. Good agreement of model predictions with experimental data is pointed out. The model was implemented into a finite element program and numerical applications on composite structures (a tensile specimen and a plate containing a central hole) are presented to illustrate the capability of the approach. Digital image correlation method was also used to measure the full-field strain in a notched specimen under tensile loading. The simulated results compared favourably with those obtained from experiments.

No abstract

Golimumab is a new approved humanized antibody for the treatment of rheumatoid arthritis (RA). This antibody belonging to biologic agents is raised against the pro‐inflammatory cytokine tumour necrosis factor‐α playing an essential role in the initiation of RA. To date, Golimumab administration for patients with RA, as indicated by USA Food and Drug Administration, is subcutaneous combined with methotrexate (MTX). Here, we have reviewed current literature with a focus on characteristics of Golimumab and also have exposed the clinical trials either using MTX or not using MTX. We have also highlighted the incoming clinical trials on Golimumab and have proposed some indications for the future studies based on a setting of clinical data and post‐marketing observational studies. These studies will advance rheumatologists’ decisions in the beginning of RA therapeutic interventions to insure the best outcomes for patients with RA and to improve their quality of life.